key: cord-0684607-mqkjqd77
authors: Su, Shan; Li, Weihua; Jiang, Shibo
title: Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
date: 2022-01-14
journal: Trends Immunol
DOI: 10.1016/j.it.2022.01.009
sha: 225961ec1132a0be116284660806b7aabb92c8ce
doc_id: 684607
cord_uid: mqkjqd77

The concurrent prevalence of SARS-CoV-2 and MERS-CoV raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-β-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus.

escape variants under the selection pressure of antibodies in COVID-19 convalescents and vaccinees, such as the VOC Omicron (B.1.1529), which harbors 32 mutations in the Spike protein, the latest SARS-CoV-2 VOC that was first reported to World Health Organization (WHO) from South Africa on 24 November 2021 [2] . Many groups are investigating this rapid mutagenesis phenomenon, by analyzing the impact of such mutants on viral entry and replication, neutralization by antibody or vaccine-induced immune responses, as well as cellular and tissue tropism. Indeed, it is not hard to envision a case where SARS-CoV-2 or Middle East respiratory syndrome coronavirus (MERS-CoV) may further evolve into a new clade, SARS-CoV-3 or MERS-CoV-2, respectively, by genetic recombination between SARS-CoV-2 and MERS-CoV. We know that SARS-CoV-2 and MERS-CoV are concurrently prevalent in the Arabian Peninsula and that genetic recombination can happen upon infection and replication of both SARS-CoV-2 and MERS-CoV in the same host, given that both viruses can infect the same cell (type-II alveolar) and both use identical transcription regulatory sequences, conserved sequences at upstream of open reading frame that can mediate discontinuous transcription of viral genome [3, 4] . Moreover, the receptor-binding domain (RBD) of SARS-CoV-2 can putatively bind to dipeptidylpeptidase 4 (DPP4), the MERS-CoV receptor--based on bioinformatics analysis combining human-virus protein interaction prediction and protein docking [5] . In fact, several cases of SARS-CoV-2 and MERS-CoV co-infection have been reported in Saudi Arabia [6] , foreboding the possibility of recombination between these two viruses.

Historically, SARS-CoV-2 was named as such based on a phylogenetic analysis, which suggests that it forms a sister clade with human SARS-CoV and bat SARS-related coronavirus (SARSr-CoV) prototypes ( Fig. 1) [7] . Following this logic, a novel SARS-CoV-3 could emerge if SARS-CoV-2 obtains a genomic segment from MERS-CoV. In addition, presumably, SARS-CoV-3 might preserve the high transmissibility potential of SARS-CoV-2, but acquire the high case-fatality rate (CFR: 35%) of MERS-CoV whereas the global CFR of SARS-CoV-2 is about 2% based on the information reported by WHO [8] . Similarly, a MERS-CoV-2 might preserve the high CFR of MERS-CoV, while potentially gaining the higher transmissibility rate of SARS-CoV-2. Such hypothesis calls for the urgent development of pan-β-CoV vaccines that could combat any possible development of future SARS-CoV-3 or MERS-CoV-2.

Currently, many research groups are working on developing CoV vaccines that are cross-J o u r n a l P r e -p r o o f Journal Pre-proof reactive to sarbecovirus, lineage B of betacoronavirus genus, (primary-level breadth), including SARS-CoV, SARS-CoV-2, and SARSr-CoVs. One study, for example, reported that mosaic nanoparticles comprising the RBDs of 4 to 8 distinct zoonotic coronaviruses, including SARS-CoV, SARS-CoV-2, and some SARSr-CoVs from bat, elicited cross-reactive immune responses against these coronaviruses in mice [9] . Although the RBD of coronaviruses mutates frequently, recent work from our laboratory showed that the neutralizing antibodies According to the protection range of a certain vaccine, we divided the coronavirus vaccines into three levels (Fig. 1) . The vaccines that can protect from infection of all sarbecoviruses, all betacoronaviruses, and all coronaviruses, fall into primary-level, middle-level, and high-level breadth, respectively. We argue that these efforts can result in successful pan-sarbecovirus (primary-level breadth) vaccines. However, as hypothesized above, a pan-β-CoV vaccine (middle-level breadth) is urgently needed to curtail the potential pandemic tide of a likely SARS-CoV-3 or MERS-CoV-2. Of note, SARS-CoV-2-reactive CD4 + T cells have been detected in the blood of around 35% of unexposed healthy individuals; moreover, in vitro analyses have shown that the numbers of activated CD4 + T cells increase after the incubation of isolated SARS-CoV2-specific CD4 + T cells with peptides derived from the Spike proteins of human endemic coronavirus 229E (belongs to α-CoV, Fig. 1 ) and OC43 (belongs to β-CoV), indicating that SARS-CoV2-specific CD4 + T could also respond to coronaviruses from other genera [14] . This study suggests the presence of cross-reactive CD4 + T cells that might be J o u r n a l P r e -p r o o f Journal Pre-proof induced by other coronaviruses in human blood. However, this does not mean that pancoronavirus vaccine (high-level breadth) could become available based on the induction of cross-reactive CD4 + T cells.

First, rare evidence suggests that T-cell responses can correlate with protection; however, many studies have shown that NAb titers induced by vaccines positively correlate with protection against symptomatic and asymptomatic SARS-CoV-2 infection in vaccinated subjects [15] . Second, T-cell immune-based pan-CoV vaccines with low neutralization immunogenicity may induce a suboptimal concentration of NAbs that may enhance SARS-CoV-2 infection by antibody-dependent enhancement (ADE) of viral entry [16] , despite the fact that researchers have reported findings in which non-neutralizing antibodies that show ADE in vitro can still protect from SARS-CoV-2 replication in monkeys and mice [17] . Therefore, while chasing panβ-CoV vaccines, taking into account both the titer of NAbs and T cell responses induced by vaccines will be an important measure for both efficacy and safety, moving forward.

We posit that it may be more realistic to develop a middle-level breadth vaccine, i.e., panβ-CoV vaccine, than a high-level vaccine, i.e., pan-CoV vaccine against the currently circulating SARS-CoV-2 and MERS-CoV, as well as their variants and possible related new clades (e.g., SARS-CoV-3 or MERS-CoV-2) to be able to equip ourselves for the possible emerging SARS-CoV-2 VOCs and SARS-CoV-3 or MERS-CoV-2 outbreaks. 

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

A new coronavirus associated with human respiratory disease in China

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

COVID-19) Dashboard

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Neutralizing antibody vaccine for pandemic and preemergent coronaviruses

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Learning from the past: development of safe and effective COVID-19 vaccines

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies